HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Reumabase.it

Search results for "non-Hodgkin's lymphoma"

A phase II study, led by Andre Goy, of the University of Texas M.D. Anderson Cancer Center, Houston, evaluated efficacy and toxicity of Bortezomib ( Velcade ) in 60 patients with relapsed or refractor ...


Hepatitis C virus ( HCV ) plays a role in the development of both hepatocellular carcinoma and B-cell non-Hodgkin's lymphoma ( B-NHL ). A multicenter study, coordinated by D Vallisa, Department of ...


Researchers at The University of Texas M. D. Anderson Cancer Center and the National Cancer Institute have found that an experimental vaccine can prime the immune system to help fight an aggressive fo ...


A Phase II clinical study demonstrated that Galiximab may be used in combination with Rituximab ( Rituxan ), and the combination may prolong event-free survival ( EFS ) in patients with relapsed or re ...


Biogen Idec has informed Healthcare Professional of new safety information which is being added to the prescribing information for Zevalin ( Ibritumomab tiuxetan ). Severe cutaneous or mucocutaneo ...


A study involving the University of Nebraska Medical Center ( UNMC ), the National Cancer Institute ( NCI ) and 10 other institutions has successfully identified the gene expression signature for Bur ...


A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, researchers at T ...


Phase III clinical trial results from Enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma ( DLBCL ). T ...


Bruton's tyrosine kinase ( BTK ) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, Ibrutinib ( Imbruvica ), a BTK inhibitor, ...


The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the Int ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...


A new analysis has indicated that higher body weight and taller stature during adolescence increase the risk of developing non-Hodgkin's lymphoma ( NHL ), a type of cancer of the lymphatic system. T ...


According to results from a phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor ( CAR ) natural killer ( NK )-cell thera ...